omniture

WuXi PharmaTech (NYSE: WX) Its Service Creed "We Are Determined to Serve You Better" is Officially Registered

2008-02-07 14:16 7179

SHANGHAI, China, Feb. 7 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE: WX), China's premier provider of pharmaceutical R&D outsourcing services is pleased to announce today that the company has received the original United States Certificate of Registration from the U.S. Patent and Trademark Office for the company’s service creed “We Are Determined to Service You Better(R)”.

(Logo: http://www.prnasia.com/sa/200708281726.jpg )

"We Are Determined to Serve You Better(R)” has been WuXi PharmaTech's service creed since the company was founded and it embodies one of the company’s core values "Client First". Governing everything the company does for its customers this service creed is firmly instilled into every employee of WuXi PharmaTech and has earned the company a solid reputation as a high quality drug R&D service provider. The successful registration of the service creed further highlights the company’s commitment to persistently achieving service excellence as well as raising the bar for IP standards in China over and over.

"We are very happy with the registration of our service creed in the U.S. Patent and Trademark Office. ‘We Are Determined to Service You Better(R)’ is what we live and breathe every day when working on each customer project. As a customer-focused company, WuXi PharmaTech is committed to meeting and exceeding the expectations of our customers and advocating IP protection," commented Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech. "With our recent acquisition of US-based biologics capabilities we will be able to provide our customers with even more and better services by creating a global outsourcing platform with best-in-class capabilities, complementary offerings, and expertise across multiple disciplines."

About WuXi PharmaTech

Founded in 2000, Shanghai-based WuXi PharmaTech is the leading China-based pharmaceutical and biotechnology R&D outsourcing company. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical and biotechnology companies with a broad and integrated portfolio of laboratory and research manufacturing services throughout the drug discovery and development process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug discovery and development by providing cost-effective and efficient outsourcing solutions that save its customers both time and money. Its operations are grouped into two segments: laboratory services, consisting of discovery chemistry, service biology, analytical, toxicology, pharmaceutical development and process development services; and research manufacturing, focusing on manufacturing of advanced intermediates and active pharmaceutical ingredients for R&D use. In 2007, its 80 customers included nine of the world's top ten pharmaceutical companies by revenue. For more information, please visit: http://www.wuxipharmatech.com .

Source: WuXi PharmaTech
Related Stocks:
NYSE:WX
collection